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Abstract
The treatment of bipolar depression is one of the most challenging fields in contemporary psychiatry.
The best data concern the antipsychotics quetiapine and the olanzapine-fluoxetine combination.
However, the usefulness of antidepressants in bipolar depression remains controversial; positive data
are available for fluoxetine but negative results have been published for paroxetine. Accumulated
knowledge so far suggests that bipolar patients need continuous administration of an antimanic agent
even during the acute depressive phase. Although our knowledge is indeed limited, the development
of guidelines for polypharmacy is necessary and should be done as soon as possible.
Introduction and content
The treatment of bipolar disorder is complex and full of
caveats for the clinician [1-4]. An important problem in
the gathering of scientific evidence lies in the low
reliability and validity of diagnosis. Another problem
is that specific and different treatments need to be
considered separately for manic, hypomanic, mixed and
bipolar depression episodes, as well as for unipolar
depression. This article will comment on the available
hard data (randomized trials) for the treatment of
bipolar depression and suggest future directions for
research.
Older studies conducted throughout the 1970s and
1980s on treatment of bipolar disorder reported positive
effects for lithium [5], carbamazepine [6], amitriptiline
[5], imipramine [7,8] and fluoxetine [9-11], however, the
studies were small and suffered from a number of
methodological drawbacks. Results from add-on studies
with imipramine as an adjunctive therapy to lithium
were negative [7,8,12].
Within the last 10 years, several phase III clinical studies
of lamotrigine (SCA100223, SCA30924, SCA40910,
SCAA2010 and SCAB2001) have demonstrated a lack
of efficacy for this agent in the treatment of bipolar
disorder [13]. There were only two small studies
reporting a positive effect of valproate in bipolar I
patients [14,15], while on the contrary, the efficacy of the
olanzapine-fluoxetine combination (OFC) against bipo-
lar I depression has been well documented [16,17].
There has been concern about the effect of olanzapine
monotherapy on the ‘depressive core’ of symptoms,
however, it is certain that patients receiving this
treatment manifest a significant improvement in symp-
toms ‘peripheral’ to those of depression, such as
insomnia, anxiety and loss of appetite [18,19]. It has
been reported that the OFC is more effective than
olanzapine monotherapy [17] and also improves many
secondary indices [20].
One study without a placebo arm suggested both
paroxetine and venlafaxine could be effective for the
treatment of bipolar depressed patients [21]. Another
comparedimipramineand paroxetinewith placebo as an
add-on to an ongoing lithim regimen and reported that
these antidepressants were beneficial for patients with
low (but not high) serum levels of lithium [22]. Other
reports suggest that adding venlafaxine, sertraline or
buproprion to a mood stabilizer increases the response
rate [23-25]. Similar findings were reported for parox-
etine [26] and citalopram [27]. Adding inositol [28] or
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in the treatment of bipolar depression.
Recent advances
During the last 3 years, there have been some important
insights from newly available data. For example, recent
negative data has emerged for drugs that had previously
shown efficacy in older studies, such as monotherapy
with lithium [30], paroxetine [31] and aripiprazole [32],
and there have been equivocal results for valproate: two
randomized controlled trials (RCTs) on the extended-
release form of valproate reported one positive and one
negative result; neither study was published (for reviews,
see [33,34]).
Quetiapine was, however, reported to be effective at
dosages of both 600 mg/day and 300 mg/day, and
produced response rates of 58.2% and 57.6%, respec-
tively (versus 36.1% for placebo), and remission rates of
52.9% in both the treated groups (versus 28.4% for
placebo) [35]. It is important to note that quetiapine
significantly improved all the Montgomery-Åsberg
Depression Rating Scale (MADRS) items corresponding
to the core symptoms of depression. Post-hoc analysis
suggests 300mg and 600mg areequally effective; despite
there being a small difference in the effect size [35,36],
they both improved secondary measures including
quality of life indices [37]. Similar results were obtained
from two more recent RCTs [30,31]. Another study
reported that an extended-release form of quetiapine
at 300 mg daily was significantly more effective than
placebo for bipolar I depression throughout the 8-week
study, with significance observed as early as day 7 [38].
In a recent double-blind, placebo-controlled study,
adding an antidepressant (either buproprion or parox-
etine) to a mood stabilizer in 179 bipolar depressed
patients was not significantly more beneficial than
placebo after 26 weeks of treatment, and the recovery
rates (23.5% in the antidepressant group versus 27.3%
in the placebo group) and switch rates to mania were
similar [39]. Thus, this study does not support the
usefulness of adjunctive antidepressant therapy. How-
ever, these data should be read with caution because
although paroxetine played a significant role in the
design, it has since been shown to be no more effective
than placebo [31]. A more recent study reported that
adding lamotrigine to lithium was more effective than
placebo in patients with bipolar depression [40].
Another recent 8-week trial studied 52 incomplete
responders treated with carbamazepine or oxcarbazepine
(600-1200 mg daily) during maintenance treatment with
lithium [41]. Although this trial focused on patients in
the ‘maintenance’ phase, the design and the results are
more relevant to the acute depressive phase because the
study sample included depressed patients. Both groups
improved with the addition of either drug but those
receiving oxcarbazepine improved significantly more in
terms of their MADRS and Hamilton Depression Rating
Scale (HDRS)-21 scores [41]. Another study reported
that adding venlafaxine, sertraline or buproprion to a
mood stabilizer increases the response rate [23].
Several reviews and meta-analytic studies of the
literature are currently available. Some suggest that
only quetiapine – and to a lesser extent, olanzapine –
show efficacy as a monotherapy for bipolar depression
[42-44]. However, two meta-analyses of four rando-
mized placebo-controlled trials (of 6 and 8 week
duration) with a total sample size of 142 patients
suggested that divalproex could also be efficacious in
acute bipolar depression, with response rates of 39.3%
for divalproex versus 17.5% for placebo. Remission
rates were 40.6% versus 24.3%, respectively [33], with
an effect size d equal to 0.35 [34]. The meta-analyisis of
the five ‘negative’ trials of lamotrigine monotherapy
(1072 patients) reported that lamotrigine was superior
to placebo in people with an HDRS score of greater than
24 but not in people with an HDRS score of less than or
equal to 24 [45]. The meta-analysis of data on
paroxetine and monoamine oxidase inhibitors
(MAOIs) in 52 patients confirmed that the effectiveness
of paroxetine was unacceptably low, but rates of
recovery with MAOIs were significantly higher than
the recovery rate with paroxetine [46].
Implications for clinical practice
Classically,thetreatmentofbipolarillnessincludestheuse
of the so-called mood stabilizers (lithium and specific
anticonvulsants), antipsychotics, and antidepressants.
Recent data dispute the efficacy of some of these agents
against bipolar depression. Only quetiapine and the OFC
are currentlyconsideredto be effective andthushave been
approved for the treatment of acute bipolar depression
[17,47,48]. Typical antipsychotics (haloperidol, chlorpro-
mazine and perphenazine) seem to have some efficacy
against acute mania but they also seem to predispose
patients to manifest dysphoria or depression [49,50]. The
dispute concerning the usefulness of antidepressants
continues; clinicians should be cautious in their use and
avoidprescribingthemasmonotherapy[1].Itisimportant
tobearinmindthattheonlypositivedataavailableforthe
use of antidepressants in treating bipolar disorder are for
fluoxetine; strong negative data still exist for paroxetine.
Since,inreallife,themajorityofbipolarpatientsdonotdo
well on monotherapy, several combination therapies and
add-on agents have been tested [23,40,41] that the
clinician should become familiar with.
Page 2 of 4
(page number not for citation purposes)
F1000 Medicine Reports 2010, 2:47 http://f1000.com/reports/medicine/content/2/47Some of the recommendations above are in relative
contrast to everyday clinical practice where clinicians do
not tailor their choice of antidepressant to a specific type
of depression and tend to use typical antipsychotics
against mania. The chronicity of bipolar depression and
its relative refractoriness to treatment might be the cause
of this discrepancy. However, treating patients as if there
is a ‘class effect’ for drugs might iatrogenically worsen the
long-term course of the illness in some patients.
When the clinician is treating a depressed bipolar
patient, it is clear that the first step should be the use
of agents with proven efficacy (from placebo-controlled
double-blind studies) against this condition. However, it
is likely that most patients will fail with such a treatment
and the clinician will be left with no hard data to rely on.
In this case, the clinician should avoid treatments with a
proven worsening effect on the long-term outcome of the
disease. Additionally, psychoeducation could constitute
a useful tool to treat bipolar depression, along with
family-focused psychoeducation and cognitive-beha-
vioral therapy [51].
Abbreviations
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